COMMUNITY CLINICAL ONCOLOGY PROGRAM

Summary

Principal Investigator: C L Loprinzi
Affiliation: Mayo Clinic
Country: USA
Abstract: DESCRIPTION: (Applicant's Description) The Mayo Clinic, through the vehicle of the North Central Cancer Treatment Group (NCCTG), will serve as a primary research base for the following 15 CCOPs: Ann Arbor Regional CCOP, Carle Cancer Center CCOP, Cedar Rapids Oncology Project CCOP, Des Moines CCOP, Duluth CCOP, Merit Care Hospital CCOP, Geisinger CCOP, Metro Minnesota CCOP, Missouri Valley Cancer Consortium CCOP, Ochsner Clinic CCOP, Illinois Oncology Research Association CCOP, Scottsdale CCOP, Siouxland Community Cancer Consortium CCOP, Toledo CCOP, and the Wichita CCOP. We will also serve as a research base for cancer control protocol activity of non-CCOP participants and for the multiple CCOPs outside of our group who contribute to intergroup cancer treatment and cancer control protocols which we lead. We will cooperate with our affiliated CCOPs in planning their program and in conducting appropriate continuing education and workshops. We will provide training and active support for their data managers and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. This will include evolving and maintaining standard reporting procedures for surgery, pathology, and radiation therapy. We will hold regular meetings of the CCOPs for review of ongoing research, planning future research, and for related professional activities. We will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP performance not only by timely review of patients, data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic randomly scheduled monitoring site visits. We will work with each CCOP participant to aid in their maturation as clinical investigators. We will assist them in developing new protocols for which they will share leadership, and we will work with them in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide them with justifiable pride in their participation in the National Cancer Program. A high priority over this grant period will be the further expansion of our cancer control efforts with incorporation of associated basic laboratory support, leading to scientifically rigorous translational research efforts.
Funding Period: 1983-09-15 - 2007-05-31
more information: NIH RePORT

Top Publications

  1. doi Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study
    Alan H Bryce
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Clin Oncol 33:353-7. 2010
  2. pmc Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thorac Oncol 3:516-20. 2008
  3. pmc Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
    Axel Grothey
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 29:421-7. 2011
  4. ncbi Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 110:2110-8. 2007
  5. pmc Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients
    Dona E C Locke
    Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    J Pain Symptom Manage 34:628-38. 2007
  6. ncbi Metrics to assess quality of life after management of early-stage lung cancer
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 17:63-7. 2011
  7. ncbi Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222
    Heidi Mc Kean
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Cancer Invest 29:266-71. 2011
  8. pmc Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma
    Matthew J Maurer
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 29:1620-6. 2011
  9. pmc A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)
    Lisa A Kottschade
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Cancer 117:1704-10. 2011
  10. ncbi Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    Robert R McWilliams
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:516-21. 2007

Scientific Experts

Detail Information

Publications144 found, 100 shown here

  1. doi Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study
    Alan H Bryce
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Clin Oncol 33:353-7. 2010
    ..Previous studies have suggested improved outcomes with a topoisomerase I inhibitor in combination with a platinum agent...
  2. pmc Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thorac Oncol 3:516-20. 2008
    ....
  3. pmc Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
    Axel Grothey
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 29:421-7. 2011
    ..In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT...
  4. ncbi Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 110:2110-8. 2007
    ..On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral neuropathy (CIPN)...
  5. pmc Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients
    Dona E C Locke
    Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    J Pain Symptom Manage 34:628-38. 2007
    ..The data suggest that the single-item LASA scales are valid for assessing QOL of cancer patients and are an appropriate alternative when a shorter instrument is warranted...
  6. ncbi Metrics to assess quality of life after management of early-stage lung cancer
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 17:63-7. 2011
    ..The primary conclusion from this work is that scientifically sound investigations into the QOL of early-stage lung cancer patients are feasible and encouraged so that the care of these patients can be optimized...
  7. ncbi Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222
    Heidi Mc Kean
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Cancer Invest 29:266-71. 2011
    ..9 months. The most common reason for conventional chemotherapy was oncologists' opinion that the cancer was aggressive, and for gefitinib alone, patients' reluctance to receive chemotherapy. Interestingly, age had no influence...
  8. pmc Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma
    Matthew J Maurer
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 29:1620-6. 2011
    ..This assay has prognostic value in plasma cell proliferative disorders. There are limited data on serum FLC in B-cell malignancies...
  9. pmc A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)
    Lisa A Kottschade
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Cancer 117:1704-10. 2011
    ..ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma...
  10. ncbi Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    Robert R McWilliams
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:516-21. 2007
    ..A combination regimen using all 4 agents could potentially increase response rates in CRC...
  11. pmc Endpoints in phase II trials for advanced non-small cell lung cancer
    Sumithra J Mandrekar
    Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Thorac Oncol 5:3-9. 2010
    ....
  12. ncbi Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3
    Debra L Barton
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Natl Cancer Inst 99:672-9. 2007
    ..Transdermal testosterone therapy has been associated with increased libido among estrogen-replete women who report low libido...
  13. pmc Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51
    Thomas B Daniels
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:218-24. 2011
    ..We sought to independently validate this prognostic index with a separate prospectively collected data set (Intergroup 86-72-51)...
  14. pmc Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial
    Steven R Alberts
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Am J Clin Oncol 35:418-23. 2012
    ..Few effective options are available for the treatment of unresectable hepatocellular carcinoma (HCC). Several phase I trials suggest promising activity of a combination of gemcitabine and docetaxel...
  15. ncbi Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer
    Yolanda I Garces
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 67:995-1001. 2007
    ..The primary goal was to identify the maximum tolerable dose (MTD) of thoracic radiation therapy (TRT) that can be given with chemotherapy and amifostine for patients with limited-stage small-cell lung cancer (LSCLC)...
  16. pmc Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
    George P Kim
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:2848-54. 2009
    ..Cross-over to the other treatment on disease progression was mandated...
  17. doi Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors
    Aminah Jatoi
    Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Thorac Oncol 5:1994-8. 2010
    ..Based on favorable preliminary clinical data and the need to identify effective, well-tolerated neoadjuvant regimens for patients with locally advanced esophageal cancer, this clinical trial was undertaken...
  18. pmc The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
    Lisa A Kottschade
    Mayo Clinic, Rochester, MN 55905, USA
    Support Care Cancer 19:1769-77. 2011
    ..Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients. Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN...
  19. pmc Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Clin Colorectal Cancer 8:88-93. 2009
    ..Although systemic chemotherapy in patients with unresectable metastatic colorectal cancer (mCRC) is palliative in nature, some patients experience long-term remission beyond 5 years consequent to treatment with chemotherapy alone...
  20. doi Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Am J Clin Oncol 33:633-6. 2010
    ..This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma...
  21. pmc Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas
    Mateusz Opyrchal
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 542:705-17. 2009
    ..We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas...
  22. pmc Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer
    Yingwei Qi
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Thorac Oncol 4:1075-82. 2009
    ..We conducted this pooled analysis to assess the prognostic value of pretreatment Quality of Life (QOL) assessments on overall survival (OS) in advanced non-small cell lung cancer (NSCLC)...
  23. pmc A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
    A Jatoi
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Ann Oncol 21:2040-4. 2010
    ..Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC...
  24. pmc A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)
    C L Loprinzi
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 20:542-9. 2009
    ..Hot flashes represent a significant problem in men undergoing androgen deprivation therapy...
  25. pmc Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
    V Roy
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Oncol 20:449-53. 2009
    ..Only one patient developed febrile neutropenia. Significant activity and favorable toxicity profile provides a basis for considering this regimen for further evaluation in phase III trials or in combination with biologic agents...
  26. pmc Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial
    Amanda R Moraska
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:3673-9. 2010
    ..Fatigue is one of the most common symptoms experienced by patients with cancer. This trial was developed to evaluate the efficacy of long-acting methylphenidate for improving cancer-related fatigue and to assess its toxicities...
  27. pmc Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:8263-9. 2008
    ..We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer...
  28. pmc Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)
    Aminah Jatoi
    Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 19:1601-7. 2011
    ..Previous studies suggest tetracycline and other antibiotics lessen the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm such findings...
  29. pmc Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    J Clin Oncol 27:11-5. 2009
    ..We conducted a cooperative group phase II study to assess antitumor activity and toxicity of sorafenib in patients with metastatic breast cancer (MBC) who had received prior treatment for their disease...
  30. pmc Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer
    Judy C Boughey
    Department of Surgery, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, 200 First Street, SW, Rochester, MN, USA
    Ann Surg Oncol 17:2702-9. 2010
    ..The aim of this study was to investigate whether contralateral prophylactic mastectomy (CPM) in addition to therapeutic mastectomy (TM) is associated with a survival advantage in high-risk women with breast cancer...
  31. pmc Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    Paul D Brown
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 26:5603-9. 2008
    ..Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial...
  32. doi Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group
    Ruta D Rao
    Rush University Medical Center, 1725 W Harrison St, Suite 809, Chicago, IL 60612, USA
    Med Oncol 28:S39-47. 2011
    ..This trial provides important toxicity information about fenretinide, a retinoid that has been used in the prevention setting, because it is the only placebo-controlled, double-blind randomized study ever performed...
  33. pmc A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA
    Charles L Loprinzi
    Mayo Clinic Rochester, Rochester, Minnesota, USA
    J Support Oncol 9:105-12. 2011
    ..This finding was confirmed by other secondary analyses. Toxicity evaluation revealed more nausea, sweating, rigors, and urinary frequency with the pilocarpine arms compared with the placebo arm...
  34. pmc Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52
    John S Bolton
    Ochsner Community Clinical Oncology Program, New Orleans, LA, USA
    Clin Colorectal Cancer 11:31-7. 2012
    ..Patients with multiple liver metastases from colorectal cancer are at high risk of recurrence after resection. Hepatic artery infusion (HAI) alternating with systemic therapy after surgical resection may improve survival after surgery...
  35. pmc Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1
    Brandi N Reeves
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Cancer 118:5171-8. 2012
    ....
  36. ncbi Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
    David P Steensma
    Mayo Clinic and Mayo Foundation, Rochester 55905, USA
    J Clin Oncol 24:1079-89. 2006
    ..To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia...
  37. pmc Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1
    Lindsay C Brown
    Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
    Support Care Cancer 21:2869-77. 2013
    ..Pelvic radiotherapy (PRT) is known to adversely affect bowel function (BF) and patient well-being. This study characterized long-term BF and evaluated quality of life (QOL) in patients receiving PRT...
  38. doi Overall survival and self-reported fatigue in patients with esophageal cancer
    M C Stauder
    Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 21:511-9. 2013
    ..A prospective cohort study was conducted to analyze whether self-reported fatigue predicts overall survival in patients with esophageal cancer...
  39. pmc North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
    Kostandinos Sideras
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Clin Breast Cancer 12:387-91. 2012
    ..Angiogenesis is an established target for the treatment of MBC. Aflibercept (VEGF-Trap) is a humanized fusion protein, which binds VEGF-A, VEGF-B, and PIGF-1 and -2...
  40. pmc The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9
    Debra L Barton
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Support Care Cancer 21:1185-92. 2013
    ....
  41. pmc A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy
    Lauren E Ta
    Department of Neurology, Mayo Clinic, College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 8:e54161. 2013
    ....
  42. ncbi Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients
    Nicole E Marshall
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Neurooncol 77:315-20. 2006
    ..To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss...
  43. pmc The relation between cancer patient treatment decision-making roles and quality of life
    Pamela J Atherton
    Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Section of Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 119:2342-9. 2013
    ..The objective of this study was to explore relations between patient role preferences during the cancer treatment decision-making process and quality of life (QOL)...
  44. ncbi Current use and surgical efficacy of laparoscopic colectomy in colon cancer
    Robert P Sticca
    Department of Surgery, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58203, USA
    J Am Coll Surg 217:56-62; discussion 62-3. 2013
    ..Current use of LC for CC is not well known...
  45. pmc Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial
    Evanthia Galanis
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 19:4816-23. 2013
    ....
  46. pmc Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2
    Debra L Barton
    Alliance Statistics and Data Center, Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Natl Cancer Inst 105:1230-8. 2013
    ..Based on pilot data, a phase III trial was developed to evaluate the efficacy of American ginseng on CRF...
  47. pmc Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature
    Krishna Patel
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    J Cancer Educ 28:770-6. 2013
    ..Of note, only the automated voice response seems capable of real-time detection of over-adherence, as observed in N0747. Oral chemotherapy adherence should be further studied, particularly from the standpoint of over-adherence...
  48. pmc CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations
    M A Province
    Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 95:216-27. 2014
    ....
  49. pmc Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)
    Charles L Loprinzi
    Charles L Loprinzi, Rui Qin, Pamela Atherton, Drew Seisler, and Axel Grothey, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN Shaker R Dakhil, Wichita Community Clinical Oncology Program, Wichita, KS Louis Fehrenbacher, Kaiser Permanente Vallejo, Vallejo, CA Kathleen A Flynn, Michigan Cancer Research Consortium, Ann Arbor, MI Rubina Qamar, Aurora Cancer Care Milwaukee West, Wauwatosa, WI and Grant C Lewis, Summit Cancer Care, Savannah, GA
    J Clin Oncol 32:997-1005. 2014
    ..Intravenous calcium and magnesium have been extensively used to reduce oxaliplatin-induced neurotoxicity. This trial was designed to definitively test whether calcium/magnesium decreases oxaliplatin-related neurotoxicity...
  50. pmc Comparison of FOLFIRI with or without cetuximab in patients with resected stage iii colon cancer; NCCTG (Alliance) intergroup trial N0147
    Jocelin Huang
    Department of Oncology, Mayo Clinic Rochester, Rochester, MN
    Clin Colorectal Cancer 13:100-9. 2014
    ..When other contemporary trials demonstrated no benefit to using irinotecan as adjuvant therapy, the FOLFIRI-containing arms were discontinued. We report the clinical outcomes for patients randomized to FOLFIRI with or without cetuximab...
  51. ncbi Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
    James N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Breast Cancer Res Treat 98:217-22. 2006
    ....
  52. pmc A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7
    Sandhya Pruthi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Menopause 19:48-53. 2012
    ..A phase III, randomized, placebo, controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes...
  53. doi A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 116:5686-93. 2010
    ..The current study was conducted to assess the efficacy and toxicity of sorafenib as front-line therapy in patients with stage IIIB (pleural effusion) or IV nonsmall cell lung cancer (NSCLC)...
  54. ncbi Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer
    MICHAEL J O'CONNELL
    Department of Medical Oncology, Allegheny General Hospital, Pittsburgh, PA, USA
    Clin Colorectal Cancer 6:133-9. 2006
    ..A clinical trial was designed to test the value of levamisole given at its maximum tolerated dose in combination with 5-FU-based chemotherapy...
  55. ncbi Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire
    Ellen M Lavoie Smith
    University of Michigan School of Nursing, 400 North Ingalls, Room 2151, Ann Arbor, MI, 48109 5482, USA
    Qual Life Res 22:2787-99. 2013
    ..This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN)...
  56. ncbi Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032
    James N Ingle
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1052-6. 2006
    ..This study was designed to examine the efficacy and toxicity of fulvestrant in patients with disease progression on a third-generation aromatase inhibitor (AI)...
  57. pmc A pilot study of long-acting octreotide for symptomatic malignant ascites
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Oncology 82:315-20. 2012
    ..This trial explored whether octreotide, an inhibitor of vascular endothelial growth factor, a putative mediator of ascites, prolongs the interval to next paracentesis...
  58. pmc Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis
    S E Schild
    Department of Radiation Oncology, Mayo Clinic, Scottsdale, USA
    Ann Oncol 23:2919-24. 2012
    ....
  59. pmc A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775
    Lisa A Kottschade
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer 119:586-92. 2013
    ..Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM)...
  60. pmc A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338
    Vivek Roy
    Hematology Oncology Division, Mayo Clinic Florida, Jacksonville, FL Mayo Clinic Arizona, Scottsdale, AZ Mayo Clinic, Rochester Duluth CCOP, Duluth, MN Wichita CCOP, Wichita, KS
    Am J Clin Oncol 36:540-4. 2013
    ..We conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel and carboplatin combination as neoadjuvant therapy for stage II or III breast cancer (BC)...
  61. ncbi Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial
    Kostandinos Sideras
    Division of Hematology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:758-67. 2006
    ..To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer...
  62. pmc Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial
    Shernan G Holtan
    Mayo Clinic Rochester, Rochester, Minnesota, United States of America
    PLoS ONE 7:e39285. 2012
    ..Efforts into developing novel diagnostic and therapeutic approaches remain important for improving the outlook for this heterogeneous group of patients...
  63. pmc KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)
    Harry H Yoon
    Authors Affiliations Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota Lehigh Valley Hospital, Allentown, Pennsylvania and Ohio State University, Columbus, Ohio
    Clin Cancer Res 20:3033-43. 2014
    ..Analysis was restricted to BRAF-wild-type tumors, because BRAF mutation was associated with poor prognosis, and BRAF and KRAS mutations are mutually exclusive...
  64. pmc Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial)
    Dan Sha
    Authors Affiliations Department of Molecular Pharmacology and Experimental Therapeutics MPET Alliance Statistics and Data Center Division of Medical Oncology Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji Nan, Shandong Province, ChinaAuthors Affiliations Department of Molecular Pharmacology and Experimental Therapeutics MPET Alliance Statistics and Data Center Division of Medical Oncology Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji Nan, Shandong Province, China
    Clin Cancer Res 20:3319-27. 2014
    ..We evaluated the LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS) in patients with stage III colon cancer who enrolled in a phase III clinical trial (NCCTG N0147)...
  65. pmc A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
    Debra L Barton
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 19:833-41. 2011
    ..The purpose of this double-blind randomized placebo-controlled trial was to evaluate a novel compounded topical gel for this problem...
  66. doi Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423
    Cheng E Chee
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2382-9. 2010
    ..We conducted a trial to confirm the efficacy and to assess the tolerability of this chemotherapy combination...
  67. pmc Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
    Howard L McLeod
    University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Clin Oncol 28:3227-33. 2010
    ..Pharmacogenetics identifies the likelihood of adverse events or response based on variants in genes involved in drug transport, metabolism, and cellular targets...
  68. pmc The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA
    Sherry L Wolf
    Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 20:625-32. 2012
    ..This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20)...
  69. pmc Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9
    Debra L Barton
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:3278-83. 2010
    ..Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief...
  70. pmc Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM
    Kurt A Jaeckle
    Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Neurooncol 99:73-80. 2010
    ..This regimen was not significantly active and radiosensitization was not observed. Non-EIAC patients with UGT1A1*28 variant alleles appear particularly sensitive to toxicity from irinotecan...
  71. pmc Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB
    Amanda R Moraska
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Support Oncol 8:128-32. 2010
    ..These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572)..
  72. pmc Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
    Steven R Alberts
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    JAMA 307:1383-93. 2012
    ..Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer...
  73. pmc The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)
    Debra L Barton
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Support Oncol 9:24-31. 2011
    ..However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with valerian exploring physiologic effects in oncology symptom management may be warranted...
  74. pmc Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1472-8. 2011
    ..The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated...
  75. pmc Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits
    Marlene H Frost
    Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Ann Surg Oncol 18:3110-6. 2011
    ....
  76. pmc Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)
    Kunal C Kadakia
    Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 118:2128-37. 2012
    ..To the authors' knowledge, this is the first randomized controlled trial to assess the efficacy of acitretin as a chemopreventive agent in nontransplantation patients at high-risk for NMSC...
  77. pmc North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme
    Jann N Sarkaria
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:468-75. 2011
    ..On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study...
  78. pmc Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5
    Sherry L Wolf
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 28:5182-7. 2010
    ..This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS...
  79. pmc Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)
    Aminah Jatoi
    Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Oncologist 15:1016-22. 2010
    ..Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes...
  80. pmc Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    Ivana N M Micallef
    Mayo Clinic Rochester, Rochester, MN, USA
    Blood 118:4053-61. 2011
    ..ER-CHOP is well tolerated and results appear promising as a combination therapy. This study was registered at www.clinicaltrials.gov as #NCT00301821...
  81. doi Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
    Joon H Uhm
    Division of Neuro Oncology, Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 80:347-53. 2011
    ..In the current study, we evaluated gefitinib, a potent EGFR inhibitor, in the treatment of adults with newly diagnosed GBM...
  82. ncbi Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 65:1106-11. 2006
    ..This trial was performed to determine the maximum tolerated dose (MTD) of radiation that can be administered with carboplatin and paclitaxel...
  83. ncbi Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 29:246-51. 2006
    ..To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC)...
  84. ncbi Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 103:111-8. 2005
    ....
  85. ncbi A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Invest 24:382-9. 2006
    ..This Phase II study was undertaken to define the efficacy and toxicity of the combination of docetaxel and irinotecan for the second-line treatment of non-small cell lung cancer (NSCLC)...
  86. ncbi Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1
    Barbara A Pockaj
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:2836-41. 2006
    ..Hot flashes can cause significant morbidity in postmenopausal women undergoing or finished with breast cancer treatment. Black cohosh has been used to treat hot flashes, but definitive clinical data about efficacy have been equivocal...
  87. ncbi Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA
    Cancer 107:767-72. 2006
    ..Thalidomide has shown promise for the treatment of patients with myelodysplastic syndrome. The current prospective multicenter study examined the efficacy and toxicity of thalidomide in adult patients with myelodysplastic syndrome...
  88. ncbi Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Ther 13:291-7. 2006
    ..Quality-of-life measures did not show any differences between the 2 groups. This study showed no evidence of benefit from flutamide as a chemoprevention agent in men with HGPIN...
  89. ncbi Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group
    Jan C Buckner
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:3871-9. 2006
    ....
  90. ncbi Can complementary and alternative medicine clinical cancer research be successfully accomplished? The Mayo Clinic-North Central Cancer Treatment Group experience
    Debra L Barton
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Soc Integr Oncol 4:143-52. 2006
    ..Well-designed and adequately powered studies can be implemented, and large numbers of patients can be accrued. The resulting research evaluations can be published in peer-reviewed medical journals...
  91. ncbi Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma
    Paul D Brown
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:5427-33. 2006
    ..To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed...
  92. ncbi Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5
    Charles L Loprinzi
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:308-12. 2007
    ..No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash control with an antidepressant alone...
  93. ncbi Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention
    Ivana T Croghan
    Nicotine Research Center, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:186-95. 2007
    ..To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention...
  94. ncbi A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Urology 69:289-94. 2007
    ..Tomatoes are rich in lycopene. This study explored the efficacy of a lycopene-rich tomato product in androgen-independent prostate cancer and the reasons patients participated in an "alternative medicine" study...
  95. ncbi Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)
    Michele Y Halyard
    Mayo Clinic, Scottsdale, AZ, USA
    Int J Radiat Oncol Biol Phys 67:1318-22. 2007
    ..This multi-institutional, double-blind, placebo-controlled trial was conducted to provide definitive evidence of this mineral's palliative efficacy...
  96. ncbi Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7
    Charles L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1409-14. 2006
    ..This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes...
  97. ncbi Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
    K F Giordano
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:652-6. 2006
    ..We therefore undertook this phase II study to test this combination in a multi-institutional, first-line clinical trial...
  98. ncbi Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial
    Patrick A Burch
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 28:195-200. 2005
    ..This 2-stage, phase II cooperative group trial examined the efficacy and toxicity of 1000 mg/m2 gemcitabine plus 25 mg/m2 cisplatin weekly for 3 weeks and repeated every 28 days for patients with previously treated metastatic breast cancer...
  99. ncbi Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005
    ..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
  100. ncbi Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 56301, USA
    Cancer 104:176-82. 2005
    ..Secondary research goals were to evaluate toxicities, tolerability, and quality of life associated with this shark cartilage product...